HomeCompareUSYNF vs ABBV

USYNF vs ABBV: Dividend Comparison 2026

USYNF yields 226.76% · ABBV yields 3.06%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 USYNF wins by $251.51M in total portfolio value
10 years
USYNF
USYNF
● Live price
226.76%
Share price
$0.88
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$251.62M
Annual income
$134,733,455.30
Full USYNF calculator →
ABBV
AbbVie Inc.
● Live price
3.06%
Share price
$217.44
Annual div
$6.65
5Y div CAGR
40.6%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$102.3K
Annual income
$24,771.77
Full ABBV calculator →

Portfolio growth — USYNF vs ABBV

📍 USYNF pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodUSYNFABBV
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, USYNF + ABBV cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
USYNF pays
ABBV pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

USYNF
Annual income on $10K today (after 15% tax)
$19,274.38/yr
After 10yr DRIP, annual income (after tax)
$114,523,437.01/yr
ABBV
Annual income on $10K today (after 15% tax)
$259.96/yr
After 10yr DRIP, annual income (after tax)
$21,056.00/yr
At 15% tax rate, USYNF beats the other by $114,502,381.00/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of USYNF + ABBV for your $10,000?

USYNF: 50%ABBV: 50%
100% ABBV50/50100% USYNF
Portfolio after 10yr
$125.86M
Annual income
$67,379,113.53/yr
Blended yield
53.54%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on ABBV right now

USYNF
No analyst data
Altman Z
1.3
Piotroski
7/9
ABBV
Analyst Ratings
27
Buy
12
Hold
1
Sell
Consensus: Buy
Price Target
$256.15
+17.8% upside vs current
Range: $223.00 — $299.00
Altman Z
2.0
Piotroski
8/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

USYNF buys
0
ABBV buys
7
PoliticianChamberTickerTypeAmountDate
Julie Johnson🏢 House$ABBV▼ Sell$1,001 - $15,0002025-12-18
Julia Letlow🏢 House$ABBV▼ Sell$1,001 - $15,0002025-12-08
Julie Johnson🏢 House$ABBV▼ Sell$1,001 - $15,0002025-11-13
Lisa McClain🏢 House$ABBV▼ Sell$1,001 - $15,0002025-10-31
Lisa McClain🏢 House$ABBV▼ Sell$1,001 - $15,0002025-10-30
Lisa McClain🏢 House$ABBV▲ Buy$1,001 - $15,0002025-10-30
John Boozman🏛 Senate$ABBV▼ Sell$1,001 - $15,0002025-08-22
John Boozman🏛 Senate$ABBV▼ Sell$1,001 - $15,0002025-08-22
Julie Johnson🏢 House$ABBV▼ Sell$1,001 - $15,0002025-08-14
John Boozman🏛 Senate$ABBV▼ Sell$1,001 - $15,0002025-08-11
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricUSYNFABBV
Forward yield226.76%3.06%
Annual dividend / share$2.00$6.65
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%40.6%
Portfolio after 10y$251.62M$102.3K
Annual income after 10y$134,733,455.30$24,771.77
Total dividends collected$238.69M$61.0K
Payment frequencyquarterlyquarterly
SectorStockHealthcare

Year-by-year: USYNF vs ABBV ($10,000, DRIP)

YearUSYNF PortfolioUSYNF Income/yrABBV PortfolioABBV Income/yrGap
1← crossover$33,376$22,675.74$11,550$430.00+$21.8KUSYNF
2$106,443$70,730.79$13,472$627.96+$93.0KUSYNF
3$324,713$210,819.25$15,906$926.08+$308.8KUSYNF
4$948,492$601,048.96$19,071$1,382.55+$929.4KUSYNF
5$2,655,703$1,640,816.23$23,302$2,095.81+$2.63MUSYNF
6$7,135,206$4,293,603.76$29,150$3,237.93+$7.11MUSYNF
7$18,415,824$10,781,153.60$37,536$5,121.41+$18.38MUSYNF
8$45,710,485$26,005,554.09$50,079$8,338.38+$45.66MUSYNF
9$109,236,565$60,326,346.04$69,753$14,065.80+$109.17MUSYNF
10$251,616,580$134,733,455.30$102,337$24,771.77+$251.51MUSYNF

USYNF vs ABBV: Complete Analysis 2026

USYNFStock

Unisync Corp., through its subsidiaries, manufactures and distributes garments in Canada. It operates in two segments, Peerless Garments LP and Unisync Group Limited. The company provides duty gear, footwear, and other accessories to fire, emergency medical services, and police and security sectors under the Carleton brand name; and service wear shirts, pants, and ties for law enforcement, fire, emergency medical, security, and correctional personnel under the Rapier brand name. It also offers professional workwear, insulated coverall, rugged workwear, outerwear, and rainwear apparel, as well as flame-resistant and safety clothing under the Hammill brand name. In addition, the company provides a line of flame-resistant work clothing under the DewLine Coveralls brand name; leatherwear; cold/wet weather outerwear garments to government organizations, including the armed forces, parks and forestry staff, RCMP, and other users under the Parkas brand name; stealth suits to various DND departments, paramilitary, police departments, and companies within the oil industry under the Gore-Tex brand name; and body measurement services under the Best-Fit name. Further, it designs, manufactures, and distributes corporate, public safety, and military uniforms under the Red the Uniform Tailor brand name; and offers corporate apparel under the York brand name, as well as public safety, and security and tactical products. The company was formerly known as ComWest Enterprise Corp. and changed its name to Unisync Corp. in August 2014. Unisync Corp. was founded in 1929 and is headquartered in Vancouver, Canada.

Full USYNF Calculator →

ABBVHealthcare

AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.

Full ABBV Calculator →
📬

Get this USYNF vs ABBV comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

USYNF vs SCHDUSYNF vs JEPIUSYNF vs OUSYNF vs KOUSYNF vs MAINUSYNF vs JNJUSYNF vs MRKUSYNF vs PFE

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.